BioCentury | Apr 16, 2021
Politics, Policy & Law

Pandemic pain: how COVID-19 has devastated patient groups

COVID-19 has devastated patient groups that prior to spring 2020 relied heavily on in-person events to raise funds, build communities and promote awareness. The cutbacks have set back scientific research,...
BioCentury | Apr 13, 2021

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Apr 9, 2021
Translation in Brief

Two ways to reverse CAR T cell exhaustion; plus a ligand and its receptor in a single vector, Cleave, Amazentis and Cello la Recherche Medicale (INSERM) Cleave Therapeutics Inc. Amazentis S.A. University of California San Diego Brain-derived neurotrophic factor (BDNF) Neurotrophic tyrosine kinase receptor 2...
BioCentury | Apr 7, 2021

Radioligand target deal with Novartis expands Artios’ runway and remit

Synthetic lethality company Artios is the latest beneficiary of Novartis’ push toward radiotherapeutics, with the pharma paying $20 million up front for rights to three targets to be discovered by the biotech for use in...
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

Though nearly every Chinese CAR T developer is prioritizing autologous programs, the key to expanding access to the modality on the price-sensitive China market is likely to be the next-generation platforms...
BioCentury | Mar 29, 2021
Product Development

March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure

Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized patients...
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting...
BioCentury | Mar 26, 2021

As valuation swells above $380M, Syncona-backed Gyroscope draws $148M series C, mulls listing

Gene therapy developer Gyroscope has another $148 million to fuel further clinical testing of its lead program for age-related macular degeneration — and the Syncona-backed, U.K.-based company could...
BioCentury | Mar 20, 2021
Politics, Policy & Law

Becerra’s confirmation, O’Connell nomination spotlight FDA commissioner choice

The Senate confirmation of Xavier Becerra as HHS secretary and President Joe Biden’s announcement that he will nominate Dawn O’Connell as HHS assistant secretary for preparedness and response shine a bright...
Items per page:
1 - 10 of 1682